Johnson & Johnson Retained Earnings (Accumulated Deficit) 2010-2024 | JNJ
Johnson & Johnson retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Johnson & Johnson retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $155.179B, a 1.73% increase year-over-year.
- Johnson & Johnson retained earnings (accumulated deficit) for 2023 were $153.843B, a 19.87% increase from 2022.
- Johnson & Johnson retained earnings (accumulated deficit) for 2022 were $128.345B, a 4.29% increase from 2021.
- Johnson & Johnson retained earnings (accumulated deficit) for 2021 were $123.06B, a 8.05% increase from 2020.
Johnson & Johnson Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$153,843 |
| 2022 |
$128,345 |
| 2021 |
$123,060 |
| 2020 |
$113,890 |
| 2019 |
$110,659 |
| 2018 |
$106,216 |
| 2017 |
$101,793 |
| 2016 |
$110,551 |
| 2015 |
$103,879 |
| 2014 |
$97,245 |
| 2013 |
$89,493 |
| 2012 |
$85,992 |
| 2011 |
$81,251 |
| 2010 |
$77,773 |
| 2009 |
$70,306 |
Johnson & Johnson Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$155,179 |
| 2024-06-30 |
$155,360 |
| 2024-03-31 |
$153,378 |
| 2023-12-31 |
$153,843 |
| 2023-09-30 |
$152,536 |
| 2023-06-30 |
$129,381 |
| 2023-03-31 |
$124,558 |
| 2022-12-31 |
$128,345 |
| 2022-09-30 |
$127,917 |
| 2022-06-30 |
$126,216 |
| 2022-03-31 |
$124,380 |
| 2021-12-31 |
$123,060 |
| 2021-09-30 |
$121,092 |
| 2021-06-30 |
$120,154 |
| 2021-03-31 |
$116,508 |
| 2020-12-31 |
$113,890 |
| 2020-09-30 |
$114,831 |
| 2020-06-30 |
$113,898 |
| 2020-03-31 |
$112,901 |
| 2019-12-31 |
$110,659 |
| 2019-09-30 |
$109,242 |
| 2019-06-30 |
$109,809 |
| 2019-03-31 |
$106,650 |
| 2018-12-31 |
$106,216 |
| 2018-09-30 |
$107,617 |
| 2018-06-30 |
$106,123 |
| 2018-03-31 |
$104,339 |
| 2017-12-31 |
$101,793 |
| 2017-09-30 |
$114,805 |
| 2017-06-30 |
$113,208 |
| 2017-03-31 |
$111,643 |
| 2016-12-31 |
$110,551 |
| 2016-09-30 |
$108,860 |
| 2016-06-30 |
$106,738 |
| 2016-03-31 |
$104,990 |
| 2015-12-31 |
$103,879 |
| 2015-09-30 |
$102,748 |
| 2015-06-30 |
$101,352 |
| 2015-03-31 |
$98,656 |
| 2014-12-31 |
$97,245 |
| 2014-09-30 |
$96,560 |
| 2014-06-30 |
$93,745 |
| 2014-03-31 |
$91,387 |
| 2013-12-31 |
$89,493 |
| 2013-09-30 |
$87,703 |
| 2013-06-30 |
$89,449 |
| 2013-03-31 |
$87,242 |
| 2012-12-31 |
$85,992 |
| 2012-09-30 |
$84,880 |
| 2012-06-30 |
$83,530 |
| 2012-03-31 |
$83,103 |
| 2011-12-31 |
$81,251 |
| 2011-09-30 |
$82,634 |
| 2011-06-30 |
$80,836 |
| 2011-03-31 |
$79,515 |
| 2010-12-31 |
$77,773 |
| 2010-09-30 |
$77,272 |
| 2010-06-30 |
$75,252 |
| 2010-03-31 |
$73,184 |
| 2009-12-31 |
$70,306 |
| 2009-09-30 |
$69,471 |
| 2009-06-30 |
$67,408 |
| 2009-03-31 |
$65,398 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$374.313B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
